{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T22:17:07Z","timestamp":1773958627335,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.seizure.2019.12.015","type":"journal-article","created":{"date-parts":[[2019,12,23]],"date-time":"2019-12-23T12:37:44Z","timestamp":1577104664000},"page":"89-95","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort"],"prefix":"10.1016","volume":"75","author":[{"given":"Anna","family":"Wie B\u00f8rsheim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anders","family":"Engeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nils Erik","family":"Gilhus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.seizure.2019.12.015_bib0005","series-title":"Epilepsy","author":"(WHO) WHO","year":"2019"},{"issue":"5","key":"10.1016\/j.seizure.2019.12.015_bib0010","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jamaneurol.2014.188","article-title":"Population-level evidence for an autoimmune etiology of epilepsy","volume":"71","author":"Ong","year":"2014","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2019.12.015_bib0015","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.eplepsyres.2009.03.003","article-title":"The descriptive epidemiology of epilepsy-a review","volume":"85","author":"Banerjee","year":"2009","journal-title":"Epilepsy Res"},{"issue":"4","key":"10.1016\/j.seizure.2019.12.015_bib0025","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE commission for classification and terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2019.12.015_bib0030","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.eplepsyres.2015.05.008","article-title":"Type 1 diabetes mellitus in people with pharmacoresistant epilepsy: prevalence and clinical characteristics","volume":"115","author":"Keezer","year":"2015","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0035","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/S1474-4422(15)00225-2","article-title":"Comorbidities of epilepsy: current concepts and future perspectives","volume":"15","author":"Keezer","year":"2016","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.seizure.2019.12.015_bib0040","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.autrev.2015.11.007","article-title":"Autoimmune epilepsy","volume":"15","author":"Greco","year":"2016","journal-title":"Autoimmun Rev"},{"issue":"s4","key":"10.1016\/j.seizure.2019.12.015_bib0045","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1528-1167.2012.03614.x","article-title":"Autoimmune and inflammatory epilepsies","volume":"53","author":"Nabbout","year":"2012","journal-title":"Epilepsia"},{"issue":"3","key":"10.1016\/j.seizure.2019.12.015_bib0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/WCO.0000000000000449","article-title":"Seizures and risk of epilepsy in autoimmune and other inflammatory encephalitis","volume":"30","author":"Spatola","year":"2017","journal-title":"Curr Opin Neurol"},{"issue":"4","key":"10.1016\/j.seizure.2019.12.015_bib0055","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1001\/jamaneurol.2016.5429","article-title":"Neurological autoantibody prevalence in epilepsy of unknown etiology","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"issue":"2\u20133","key":"10.1016\/j.seizure.2019.12.015_bib0060","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0920-1211(00)00180-7","article-title":"Glutamic acid decarboxylase autoantibodies in controlled and uncontrolled epilepsy: a pilot study","volume":"42","author":"Kwan","year":"2000","journal-title":"Epilepsy Res"},{"issue":"12","key":"10.1016\/j.seizure.2019.12.015_bib0065","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1111\/j.1528-1167.2005.00344.x","article-title":"Somatic comorbidity of epilepsy in the general population in Canada","volume":"46","author":"Tellez-Zenteno","year":"2005","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2019.12.015_bib0070","doi-asserted-by":"crossref","first-page":"e1532","DOI":"10.1542\/peds.2011-0245","article-title":"Psychiatric and medical comorbidity and quality of life outcomes in childhood-onset epilepsy","volume":"128","author":"Baca","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.seizure.2019.12.015_bib0075","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.seizure.2017.10.017","article-title":"Potential factors impacting health-related quality of life among patients with epilepsy: results from the United Arab Emirates","volume":"53","author":"Alsaadi","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.12.015_bib0080","series-title":"Overview of the national health registries","author":"Health NIoP","year":"2016"},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0085","first-page":"129","article-title":"Establishment of the nationwide Norwegian Prescription Database (NorPD) \u2013 new opportunities for research in pharmacoepidemiology in Norway","volume":"18","author":"Furu","year":"2008","journal-title":"Nor Epidemiol"},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0090","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/j.1742-7843.2009.00494.x","article-title":"The Nordic countries as a cohort for pharmacoepidemiological research","volume":"106","author":"Furu","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.seizure.2019.12.015_bib0095","unstructured":"Methodology WHOWCCfDS. Purpose of the ATC\/DDD system [Available from: https:\/\/www.whocc.no\/atc_ddd_methodology\/purpose_of_the_atc_ddd_system\/."},{"issue":"7","key":"10.1016\/j.seizure.2019.12.015_bib0100","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1111\/ene.12439","article-title":"Total drug treatment and comorbidity in myasthenia gravis: a population-based cohort study","volume":"21","author":"Andersen","year":"2014","journal-title":"Eur J Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2019.12.015_bib0105","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMp1704633","article-title":"Gabapentin and pregabalin for pain \u2014 is increased prescribing a cause for concern?","volume":"377","author":"Goodman","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seizure.2019.12.015_bib0110","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.4045\/tidsskr.15.0454","article-title":"Forekomst av epilepsi i de nordiske landene","volume":"135","author":"Syvertsen","year":"2015","journal-title":"Tisskr Nor Laegeforen"},{"key":"10.1016\/j.seizure.2019.12.015_bib0115","series-title":"Diabetes","author":"Helsedirektoratet","year":"2018"},{"issue":"6","key":"10.1016\/j.seizure.2019.12.015_bib0120","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1007\/s00125-016-3929-0","article-title":"Risk of epilepsy in type 1 diabetes mellitus: a population-based cohort study","volume":"59","author":"Chou","year":"2016","journal-title":"Diabetologia"},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0125","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1007\/s00125-016-4142-x","article-title":"Type 1 diabetes mellitus and risk of incident epilepsy: a population-based, open-cohort study","volume":"60","author":"Dafoulas","year":"2017","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0130","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.eplepsyres.2011.03.009","article-title":"Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: a population-based study","volume":"95","author":"Wirrell","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2019.12.015_bib0135","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.mam.2014.12.004","article-title":"Immunogenetics of type 1 diabetes mellitus","volume":"42","author":"Morran","year":"2015","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.seizure.2019.12.015_bib0140","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.seizure.2016.11.013","article-title":"Physical and mental health comorbidities of epilepsy: population-based cross-sectional analysis of 1.5 million people in Scotland","volume":"45","author":"Weatherburn","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.12.015_bib0145","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.seizure.2017.03.011","article-title":"Effects of antiepileptic drugs on thyroid hormone function in epilepsy patients","volume":"48","author":"Shih","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.seizure.2019.12.015_bib0150","article-title":"The effect of antiepileptic drugs on thyroid hormonal function: valproic acid and phenobarbital","author":"G\u00fcng\u00f6r","year":"2018","journal-title":"Acta Neurol Belg"},{"key":"10.1016\/j.seizure.2019.12.015_bib0155","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.seizure.2015.02.022","article-title":"Interactions between antiepileptic drugs and hormones","volume":"28","author":"Svalheim","year":"2015","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0160","first-page":"82","article-title":"Hypothyroidism - new aspects of an old disease","volume":"14","author":"Kostoglou-Athanassiou","year":"2010","journal-title":"Hippokratia"},{"key":"10.1016\/j.seizure.2019.12.015_bib0165","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.neuint.2017.11.019","article-title":"Anti-thyroid antibodies and thyroid function in anti-N-methyl-d-aspartate receptor encephalitis","volume":"113","author":"Lin","year":"2018","journal-title":"Neurochem Int"},{"key":"10.1016\/j.seizure.2019.12.015_bib0170","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.imlet.2017.02.010","article-title":"Modulating the function of the immune system by thyroid hormones and thyrotropin","volume":"184","author":"Jara","year":"2017","journal-title":"Immunol Lett"},{"key":"10.1016\/j.seizure.2019.12.015_bib0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jns.2016.04.039","article-title":"Anti-thyroid antibodies and thyroid function in neuromyelitis optica spectrum disorders","volume":"366","author":"Wang","year":"2016","journal-title":"J Neurol Sci"},{"issue":"10047","key":"10.1016\/j.seizure.2019.12.015_bib0180","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0140-6736(16)00278-6","article-title":"Hyperthyroidism","volume":"388","author":"De Leo","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.seizure.2019.12.015_bib0185","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jocn.2017.06.067","article-title":"Treatment of epilepsy in patients with myasthenia gravis: is really harder than it looks?","volume":"44","author":"Lorenzoni","year":"2017","journal-title":"J Clin Neurosci"},{"issue":"198","key":"10.1016\/j.seizure.2019.12.015_bib0190","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","author":"Andersen","year":"2014","journal-title":"Acta Neurol Scand, Suppl"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0195","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/ene.12599","article-title":"Myasthenia gravis and risks for comorbidity","volume":"22","author":"Gilhus","year":"2015","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.seizure.2019.12.015_bib0200","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/ana.20703","article-title":"Diagnostic criteria for multiple sclerosis: 2005 revisions to the \"McDonald Criteria","volume":"58","author":"Polman","year":"2005","journal-title":"Ann Neurol"},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0205","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann Neurol"},{"issue":"24","key":"10.1016\/j.seizure.2019.12.015_bib0210","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1212\/WNL.0000000000004740","article-title":"Epilepsy in multiple sclerosis: a nationwide population-based register study","volume":"89","author":"Burman","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.seizure.2019.12.015_bib0215","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.seizure.2017.09.022","article-title":"The prevalence and characteristics of epilepsy in patients with multiple sclerosis in Nordland county, Norway","volume":"52","author":"Benjaminsen","year":"2017","journal-title":"Seizure"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0220","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/S1525-5050(02)00646-7","article-title":"Epilepsy and multiple sclerosis","volume":"4","author":"Poser","year":"2003","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.seizure.2019.12.015_bib0225","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.phrs.2016.03.003","article-title":"Addressing the burden of epilepsy: many unmet needs","volume":"107","author":"Beghi","year":"2016","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1528-1167.2006.00387.x","article-title":"Epilepsy in Colombia: epidemiologic profile and classification of epileptic seizures and syndromes","volume":"47","author":"Velez","year":"2006","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2019.12.015_bib0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S1474-4422(11)70096-5","article-title":"Autoantibodies associated with diseases of the CNS: new developments and future challenges","volume":"10","author":"Vincent","year":"2011","journal-title":"Lancet Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2019.12.015_bib0240","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1111\/j.1528-1167.2007.01500.x","article-title":"Cyclophosphamide for anti-GAD antibody-positive refractory status epilepticus","volume":"49","author":"Kanter","year":"2008","journal-title":"Epilepsia"},{"issue":"18","key":"10.1016\/j.seizure.2019.12.015_bib0245","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1212\/WNL.0000000000000383","article-title":"Utility of an immunotherapy trial in evaluating patients with presumed autoimmune epilepsy","volume":"82","author":"Toledano","year":"2014","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.seizure.2019.12.015_bib0250","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1111\/epi.12142","article-title":"Autoimmune epilepsy in children: case series and proposed guidelines for identification","volume":"54","author":"Suleiman","year":"2013","journal-title":"Epilepsia"},{"issue":"1","key":"10.1016\/j.seizure.2019.12.015_bib0255","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1684\/j.1950-6945.2004.tb00043.x","article-title":"The mortality of epilepsy revisited","volume":"6","author":"Gaitatzis","year":"2004","journal-title":"Epileptic Disord."},{"issue":"2","key":"10.1016\/j.seizure.2019.12.015_bib0260","doi-asserted-by":"crossref","DOI":"10.1684\/j.1950-6945.2004.tb00053.x","article-title":"Antiepileptic drugs: indications other than epilepsy","volume":"6","author":"Spina","year":"2004","journal-title":"Epileptic Disord"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119306582?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131119306582?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T01:54:08Z","timestamp":1761011648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131119306582"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":52,"alternative-id":["S1059131119306582"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2019.12.015","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epilepsy and autoimmune diseases: Comorbidity in a national patient cohort","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2019.12.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd on behalf of British Epilepsy Association.","name":"copyright","label":"Copyright"}]}}